3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Gemcitabine
74
Capecitabine
60
Paclitaxel
59
Fluorouracil
58
Oxaliplatin
57
Bevacizumab
51
Docetaxel
50
Leucovorin
48
Nivolumab
40
Cisplatin
40
Irinotecan
39
Carboplatin
37
Cetuximab
34
pembrolizumab
32
Radiosurgery
32
Trastuzumab
30
Radiotherapy
27
Everolimus
24
Sorafenib
23
Pemetrexed
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Ipilimumab
19
Cyclophosphamide
19
Panitumumab
18
Zoledronic Acid
17
Lapatinib
17
Erlotinib Hydrochloride
17
Prednisone
16
pazopanib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasm Metastasis
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts